Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
S&P 500 Rises as AI Stocks and Small Caps Rally on Strong Earnings Outlook 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
